Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of TransEnterix, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of TransEnterix, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016

The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of TransEnterix, Inc. (“TransEnterix” or the “Company”) (NYSE MKT: TRXC) between February 10, 2016 and May 10, 2016.

You are hereby notified that a class action has been commenced in the USDC for the Eastern District of North Carolina. If you purchased or otherwise acquired TransEnterix securities between February 10, 2016 and May 10, 2016, your rights may be affected by this action. To get more information go to:

http://www.zlk.com/pslra/transenterix

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

TransEnterix developed The SurgiBot ™ System, a surgical platform designed to be minimally invasive and allow for multiple instruments to be introduced and deployed through an incision. The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that (a) there were deficiencies within the Company’s 510(k) application to the Food and Drug Administration which undermined the likelihood that the SurgiBot would receive FDA clearance; (b) that as a result of these deficiencies, TransEnterix would be unable to commercialize the SurgiBot in 2016; and (c) consequently, the Company’s ability to obtain approval for and commercialize its other robotic surgery platforms in the U.S. would be impaired.

If you suffered a loss in TransEnterix you have until August 1, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Tel: 212-363-7500
Toll Free: 877-363-5972
Fax: 212-363-7171
www.zlk.com